Fractional CIPO for High-Growth Companies
You are scaling. Your IP should be giving you options.
A patent portfolio is not a trophy case. It is a hand of cards. IP-backed loans. Cross-licenses. Blocking patents. Joint venture leverage. Acquisition positioning. Enforcement. Each of these tools requires someone inside the company to pick it up and use it.
Your attorney will not call to say “you should collateralize your portfolio” or “there is a licensing opportunity against your competitor’s new product.” That is not their job. It is not on their radar.
A fractional Chief IP Officer gives you and your board the framework to see the options and act on them.
What Changes When This Role Exists
Uncertainty gets replaced with a plan
Every patent maps to a deployment path: licensing, cross-license position, acquisition premium, enforcement, or lending collateral. Your board sees business options, not a cost line. The virtuous cycle starts. Strong patents protect revenue. Enforceable patents make the portfolio lendable. The loan funds growth. Growth produces more inventions. The portfolio gets stronger.
You set the competitive agenda
Instead of reacting to what competitors have done, you change their behavior before they act. Where can you force a competitor to license before they execute their roadmap? What unsolved problems will every competitor face, and can you get there first?
The portfolio positions the company for acquisition
Acquirers do not buy your patents to protect your products. They buy them to use against their competitors. Claims that describe competitors’ products, not just yours, command premiums. Weak patents close doors.
IP-backed lending becomes available
Your patents are collateral. IP lenders evaluate the overlap between your patents and your revenue. I map each patent to the revenue it protects and structure the portfolio for lender evaluation. Non-dilutive capital. Nobody’s ownership stake shrinks.
Collaborations are structured to protect your position
When a larger company gets access to your technology through a collaboration, the sophisticated ones file improvement patents on what they learn. I anticipate this with joint inventorship provisions, improvement filings during the collaboration, and monitoring of the partner’s patent activity.
A patent that describes your own product is a diary entry. A patent that describes the competitor’s product is leverage.
The difference is not the technology. It is whether someone is making filing decisions in business terms.
The Mistakes We See
These patterns destroy patent value at high-growth companies. They happen when filing decisions are driven by enthusiasm or momentum instead of structured analysis.
Describing your own product instead of the competitor’s
A valuable patent reads on the competitor’s product, not yours. When the lens stays on your implementation, the claims become an implementation diary. Your competitor builds something close enough to compete and far enough away to avoid infringement. The patent exists to constrain what the competitor can build.
When filing momentum replaces structured review
The CEO delegates to the CTO. The CTO’s incentive is patent count. Twenty patents that cannot be enforced are worth less than two that can. The CTO-attorney dynamic creates momentum that resists structured review.
Patents sitting in a drawer
The portfolio grows. Nothing happens with it. No licensing revenue. No competitor deterrence. No acquisition leverage. No lending collateral. Every deployment tool exists and is available today. What is missing is the structure to put them to work.
No plan for what to do when someone infringes
You can see a competitor using your technology. You may be certain of it. But between suspecting infringement and acting on it is a gap most companies never cross. They have not done a claims analysis. They have not assessed damages. They are afraid of the cost, afraid of losing, and afraid of being called a patent troll. So they do nothing. Or they jump into litigation recklessly. Enforcement does not have to mean expensive litigation. It can mean an Amazon takedown, a tradeshow booth shutdown, a cross-license, leverage in a partnership negotiation, or positioning the company for acquisition. The missing piece is a balanced assessment and someone to guide the decision.
Not watching what competitors file
Most companies file patents on their own inventions but never look at what the competition has filed. Competitors’ applications publish eighteen months later. By the time you discover them through a lawsuit, every option is bad.
Letting a partner build a moat around your technology
A sensor company entered a licensing agreement with a multinational. The multinational got under the hood and filed a dozen improvement patents. Completely legal. The original patents were expiring. The improvement patents would be enforceable for twenty more years.
Accidental continuation families
Most patent families are accidents. Opportunistic follow-on filings that say the same thing multiple times, tied together by terminal disclaimers, aging out before the business reaches scale. A planned continuation strategy names specific competitors, markets, and implementation paths.
The Engagement
I start with the business. Products, revenue, customers, competitors, growth trajectory, capital strategy, exit objectives. The portfolio gets evaluated against the company as it operates and within its competitive environment. After 90 days: classified portfolio with deployment paths, competitive landscape with blocking opportunities, invention framework, prosecution playbooks, outside counsel alignment, board-ready IP position.
Phase 2 is a standing executive function. Strategy calls. Invention review. Prosecution oversight. Outside counsel management across multiple firms. Competitive monitoring. Deployment support for lending, licensing, enforcement, cross-licenses, and transactions.
Phase 1 scope and investment depend on portfolio size, competitive landscape, and deployment objectives.
Common Questions
We already have patents. Why do we need this now?
Having patents and having a patent strategy are different things. Most high-growth portfolios were built on momentum. I evaluate what you have, map it against the competitive landscape, identify gaps, and build a plan that ties IP to your capital strategy and exit.
How does IP-backed lending work?
IP lenders evaluate your patents as collateral. I map each patent to revenue, structure the portfolio for underwriting, and manage the process. Non-dilutive capital.
What about cross-licensing and partnerships?
Patents are trading cards. The company with the better hand gets better terms. I make sure you know what you hold and how to play it. And when a partner gets under the hood, I monitor their filings.
Should we be filing blocking patents?
Often, yes. One company patented laser-based alternatives to their own ultrasonic technology, not because they were building a laser product, but because they knew competitors were. Pure blocking plays.
How does IP factor into an acquisition?
The acquirer’s counsel examines every patent during diligence. They look for prosecution history problems, claim weaknesses, and uncited prior art. Weak patents signal that the company does not understand its IP. I build a portfolio that survives scrutiny.
How does this work with my existing patent attorney?
They keep drafting and prosecuting, but with clear direction and fast decisions. It becomes a working partnership.
What do the first 90 days look like?
Month one: portfolio assessment against competitive landscape. Lending readiness. Month two: competitive mapping, blocking opportunities, continuation strategy, cross-license positioning. Month three: deployment plan with a board-ready presentation and next steps.
